The global Psoriatic Arthritis (PsA) Treatment Market is expected to grow from USD 11,973.7 million in 2024 to USD 25,375.6 ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives ...

William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.

Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session ...

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...